





## VF001002 CLINICAL TRIAL UPDATE: One-hundredth patient recruited in strong start to 2018

**Brisbane, Australia 8<sup>th</sup> February 2018:** Factor Therapeutics Limited (ASX: FTT, the “Company”), an Australian biomedical company developing therapeutics for advanced wound care, is pleased to announce the one-hundredth patient has been recruited into the VF00102 clinical trial. This milestone ensures the trial remains on track to complete recruitment within the second quarter, potentially in April.

In a strong start to the new year, during January 9 patients were randomised into the treatment phase of the study and 23 new patients were entered into the two-week screening phase, with 12 patients still in screening at the end of the month.

“It’s excellent to see the trial returning so quickly to the trajectory we reported before the year-end break. The majority of our sites are all actively contributing, and enthusiasm among our investigators is high as we get closer to completion,” said Dr Ros Wilson, CEO of Factor Therapeutics. “The number of patients in screening is particularly exciting, as this is the step that leads to randomisation. We are continuing our active management strategy of the trial and working closely with our investigators to deliver a high-quality Phase 2 dataset”.



-ENDS-

### Contact for Further Information:

Dr. Rosalind Wilson  
Chief Executive Officer  
Factor Therapeutics Limited  
[r.wilson@factor-therapeutics.com](mailto:r.wilson@factor-therapeutics.com)

### About Factor Therapeutics

Factor Therapeutics Limited (“Factor”) is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF-001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company’s platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor’s shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <https://factor-therapeutics.com>